Tammy M. Martin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tammy M. Martin has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Justine R. Smith
College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia
6 shared publications James T. Rosenbaum
Dr. Rosenbaum has received consulting fees, speaking fees, and/or honoraria from Abbott (less than $10,000 each) and owns stock or stock options in Amgen
4 shared publications- James Todd Rosenbaum
Legacy Devers Eye Institute Portland Oregon
3 shared publications - Dongseok Choi
School of Public Health Oregon Health & Science University‐Portland State University Portland Oregon USA
2 shared publications - Stephen R. Planck
Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University, 3375 SW Terwilliger Blvd, Portland, OR, 97239, USA
2 shared publications Trudy M. Doyle
2 shared publications
Latest Publications
- 1 January 2016
- Published by Springer Nature
- p. 673-680
Familial Uveitis
- 1 January 2016
- Published by Springer Nature
- p. 115-122
Genetics
- Open Access
- 9 November 2009
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 11 (6) , R168
Insights in to the pathogenesis of axial spondyloarthropathy based on gene expression profiles
Introduction: Axial spondyloarthropathy (SpA) is a group of inflammatory diseases, with ankylosing spondylitis as the prototype. SpA affects the axial skeleton, entheses, joints and, at times, the eyes. This study tested the hypothesis that SpA is characterized by a distinct pattern of gene expression in peripheral blood of affected individuals compared with healthy controls. Methods: High-density, human GeneChip® probe arrays were used to profile mRNA of peripheral blood cells from 18 subjects with SpA and 25 normal individuals. Samples were processed as two separate sets at different times (11 SpA + 12 control subjects in primary set (Set 1); 7 SpA+ 13 control subjects in the validation set (Set 2)). Blood samples were taken at a time when patients were not receiving systemic immunomodulatory therapy. Differential expression was defined as a 1.5-fold change with a q value < 5%. Gene ontology and pathway information were also studied. Results: Signals from 134 probe sets (representing 95 known and 12 unknown gene transcripts) were consistently different from controls in both Sets 1 and 2. Included among these were transcripts for a group of 20 genes, such as interleukin-1 (IL-1) receptors 1 and 2, Nod-like receptor family, pyrin domain containing 2 (NLRP2), secretory leukocyte peptidase inhibitor (SLPI), secreted protein acidic and rich in cysteine (SPARC), and triggering receptor expressed on myeloid cells 1 (TREM-1) that are clearly related to the immune or inflammatory response and a group of 4 transcripts that have a strong role in bone remodeling. Conclusions: Our observations are the first to implicate SPARC, SLPI, and NLRP2, a component of the innate immune system, in the pathogenesis of SpA. Our results also indicate a possible role for IL-1 and its receptors in SpA. In accord with the bone pathology component of SpA, we also found that expression levels of transcripts reflecting bone remodeling factors are also distinguishable in peripheral blood from patients with SpA versus controls. These results confirm some previously identified biomarkers implicated in the pathogenesis of SpA and also point to novel mediators in this disease.
- 9 November 2009
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 11 (6) , R168
Open AccessInsights in to the pathogenesis of axial spondyloarthropathy based on gene expression profiles
Introduction: Axial spondyloarthropathy (SpA) is a group of inflammatory diseases, with ankylosing spondylitis as the prototype. SpA affects the axial skeleton, entheses, joints and, at times, the eyes. This study tested the hypothesis that SpA is characterized by a distinct pattern of gene expression in peripheral blood of affected individuals compared with healthy controls. Methods: High-density, human GeneChip® probe arrays were used to profile mRNA of peripheral blood cells from 18 subjects with SpA and 25 normal individuals. Samples were processed as two separate sets at different times (11 SpA + 12 control subjects in primary set (Set 1); 7 SpA+ 13 control subjects in the validation set (Set 2)). Blood samples were taken at a time when patients were not receiving systemic immunomodulatory therapy. Differential expression was defined as a 1.5-fold change with a q value < 5%. Gene ontology and pathway information were also studied. Results: Signals from 134 probe sets (representing 95 known and 12 unknown gene transcripts) were consistently different from controls in both Sets 1 and 2. Included among these were transcripts for a group of 20 genes, such as interleukin-1 (IL-1) receptors 1 and 2, Nod-like receptor family, pyrin domain containing 2 (NLRP2), secretory leukocyte peptidase inhibitor (SLPI), secreted protein acidic and rich in cysteine (SPARC), and triggering receptor expressed on myeloid cells 1 (TREM-1) that are clearly related to the immune or inflammatory response and a group of 4 transcripts that have a strong role in bone remodeling. Conclusions: Our observations are the first to implicate SPARC, SLPI, and NLRP2, a component of the innate immune system, in the pathogenesis of SpA. Our results also indicate a possible role for IL-1 and its receptors in SpA. In accord with the bone pathology component of SpA, we also found that expression levels of transcripts reflecting bone remodeling factors are also distinguishable in peripheral blood from patients with SpA versus controls. These results confirm some previously identified biomarkers implicated in the pathogenesis of SpA and also point to novel mediators in this disease.
- Open Access
- 29 January 2009
- Published by Wiley in Arthritis & Rheumatism
- Vol. 60 (2) , 611-618
The NOD2 defect in Blau syndrome does not result in excess interleukin‐1 activity
Objective: Blau syndrome is a rare, autosomal‐dominant, autoinflammatory disorder characterized by granulomatous arthritis, uveitis, and dermatitis. Genetics studies have shown that the disease is caused by single nonsynonymous substitutions in NOD‐2, a member of the NOD‐like receptor or NACHT–leucine‐rich repeat (NLR) family of intracellular proteins. Several NLRs function in the innate immune system as sensors of pathogen components and participate in immune‐mediated cellular responses via the caspase 1 inflammasome. Mutations in a gene related to NOD‐2, NLRP3, are responsible for excess caspase 1–dependent interleukin‐1β (IL‐1β) in cryopyrinopathies such as Muckle‐Wells syndrome. Furthermore, functional studies demonstrate that caspase 1–mediated release of IL‐1β also involves NOD‐2. The aim of this study was to test the hypothesis that IL‐1β may mediate the inflammation seen in patients with Blau syndrome.Methods: IL‐1β release was measured in peripheral blood mononuclear cells cultured in vitro, obtained from 5 Blau syndrome individuals with a NOD2 (CARD15) mutation.Results: We observed no evidence for increased IL‐1β production in cells obtained from subjects with Blau syndrome compared with healthy control subjects. Furthermore, we presented 2 cases of Blau syndrome in which recombinant human IL‐1 receptor antagonist (anakinra) was ineffective treatment.Conclusion: Taken together, these data suggest that in contrast to related IL‐1β–dependent autoinflammatory cryopyrinopathies, Blau syndrome is not mediated by excess IL‐1β or other IL‐1 activity.
- 29 January 2009
- Published by Wiley in Arthritis & Rheumatism
- Vol. 60 (2) , 611-618
Open AccessThe NOD2 defect in Blau syndrome does not result in excess interleukin‐1 activity
Objective: Blau syndrome is a rare, autosomal‐dominant, autoinflammatory disorder characterized by granulomatous arthritis, uveitis, and dermatitis. Genetics studies have shown that the disease is caused by single nonsynonymous substitutions in NOD‐2, a member of the NOD‐like receptor or NACHT–leucine‐rich repeat (NLR) family of intracellular proteins. Several NLRs function in the innate immune system as sensors of pathogen components and participate in immune‐mediated cellular responses via the caspase 1 inflammasome. Mutations in a gene related to NOD‐2, NLRP3, are responsible for excess caspase 1–dependent interleukin‐1β (IL‐1β) in cryopyrinopathies such as Muckle‐Wells syndrome. Furthermore, functional studies demonstrate that caspase 1–mediated release of IL‐1β also involves NOD‐2. The aim of this study was to test the hypothesis that IL‐1β may mediate the inflammation seen in patients with Blau syndrome.Methods: IL‐1β release was measured in peripheral blood mononuclear cells cultured in vitro, obtained from 5 Blau syndrome individuals with a NOD2 (CARD15) mutation.Results: We observed no evidence for increased IL‐1β production in cells obtained from subjects with Blau syndrome compared with healthy control subjects. Furthermore, we presented 2 cases of Blau syndrome in which recombinant human IL‐1 receptor antagonist (anakinra) was ineffective treatment.Conclusion: Taken together, these data suggest that in contrast to related IL‐1β–dependent autoinflammatory cryopyrinopathies, Blau syndrome is not mediated by excess IL‐1β or other IL‐1 activity.
- 1 September 2007
- Vol. 34 (9) , 1945-7
Granulomatous nephritis associated with R334Q mutation in NOD2.
- 1 September 2007
- Vol. 34 (9) , 1945-7
Granulomatous nephritis associated with R334Q mutation in NOD2.
- Open Access
- 7 January 2005
- Published by Wiley in Arthritis & Rheumatism
- Vol. 52 (1) , 269-274
A locus on chromosome 9p predisposes to a specific disease manifestation, acute anterior uveitis, in ankylosing spondylitis, a genetically complex, multisystem, inflammatory disease
Objective: Uveitis or intraocular inflammation is a major cause of visual loss. Acute anterior uveitis (AAU) affects ∼40% of patients with ankylosing spondylitis (AS) but also affects patients with no evidence of spondylarthritis. We sought to determine whether a unique genetic region could be implicated in a specific manifestation—AAU—of a multisystem, inflammatory, genetically complex disease, AS.Methods: Individuals from families multiplex for AAU were genotyped at 400 markers representing the ABI PRISM linkage map MD‐10, and at the HLA–B, DRB1, DQA1, DQB1, and DPB1 alleles. Among the family members with AAU, 76 affected sibpairs were analyzed (6 without concomitant AS, 12 discordant for AS, and 58 concordant for AS). Two‐point and multipoint nonparametric linkage analyses were performed, and 1‐parameter allele‐sharing model logarithm of odds (LOD) scores were determined.Results: As previously reported for AS, linkage at the major histocompatibility complex region (chromosome 6p21) was evident, exhibiting the highest multipoint LOD score (4.96 at marker HLA–B). Strong linkage was seen at a region on chromosome 9p21–9p24, with a LOD score of 3.72 at marker D9S157. When compared with a companion cohort of AS families, the linkage at this region was found in association with AAU but not with AS. A third region on chromosome 1q23–1q31 was observed to have suggestive linkage (LOD 2.05 at marker D1S238), which overlaps with a region associated with AS.Conclusion: This is the first study in which a genetic region for AAU has been identified by genome‐wide scan. Even though AS was highly prevalent in this cohort of families, a locus at chromosome 9p21–9p24 was identified that uniquely associates with AAU. Identifying the genetic perturbation at this region may advance our understanding of the mechanisms involved in tissue‐specific pathology of complex inflammatory diseases.
- 7 January 2005
- Published by Wiley in Arthritis & Rheumatism
- Vol. 52 (1) , 269-274
Open AccessA locus on chromosome 9p predisposes to a specific disease manifestation, acute anterior uveitis, in ankylosing spondylitis, a genetically complex, multisystem, inflammatory disease
Objective: Uveitis or intraocular inflammation is a major cause of visual loss. Acute anterior uveitis (AAU) affects ∼40% of patients with ankylosing spondylitis (AS) but also affects patients with no evidence of spondylarthritis. We sought to determine whether a unique genetic region could be implicated in a specific manifestation—AAU—of a multisystem, inflammatory, genetically complex disease, AS.Methods: Individuals from families multiplex for AAU were genotyped at 400 markers representing the ABI PRISM linkage map MD‐10, and at the HLA–B, DRB1, DQA1, DQB1, and DPB1 alleles. Among the family members with AAU, 76 affected sibpairs were analyzed (6 without concomitant AS, 12 discordant for AS, and 58 concordant for AS). Two‐point and multipoint nonparametric linkage analyses were performed, and 1‐parameter allele‐sharing model logarithm of odds (LOD) scores were determined.Results: As previously reported for AS, linkage at the major histocompatibility complex region (chromosome 6p21) was evident, exhibiting the highest multipoint LOD score (4.96 at marker HLA–B). Strong linkage was seen at a region on chromosome 9p21–9p24, with a LOD score of 3.72 at marker D9S157. When compared with a companion cohort of AS families, the linkage at this region was found in association with AAU but not with AS. A third region on chromosome 1q23–1q31 was observed to have suggestive linkage (LOD 2.05 at marker D1S238), which overlaps with a region associated with AS.Conclusion: This is the first study in which a genetic region for AAU has been identified by genome‐wide scan. Even though AS was highly prevalent in this cohort of families, a locus at chromosome 9p21–9p24 was identified that uniquely associates with AAU. Identifying the genetic perturbation at this region may advance our understanding of the mechanisms involved in tissue‐specific pathology of complex inflammatory diseases.
- 1 November 2003
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 136 (5) , 933-935
Uveitis in patients with sarcoidosis is not associated with mutations in NOD2 (CARD15)
- 1 November 2003
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 136 (5) , 933-935
Uveitis in patients with sarcoidosis is not associated with mutations in NOD2 (CARD15)
- 1 September 2002
- Published by Dougmar Publishing Group, Inc.
- Vol. 15 (3) , 259-70
Immune mechanisms in uveitis. What can be learned from in vivo imaging?
In many aspects, in vivo imaging is superior to other techniques, such as conventional histology, because it allows the stepwise process of leukocyte migration to be dissected. The potential uses of the in vivo imaging techniques have yet to be achieved. The transfer of lymphocytes with fluorescent dyes can be marked. APCs that ingest fluorescent antigen and use fluorescent antibodies specifically to label different types of APCs in the anterior segment can be identified. Combining these techniques could result in more exciting insights into uveitis and the mechanisms of the immune system. For example, one can confidently expect to be able to observe the extravasation of CFSE-marked DO11.10 T cells and their subsequent interaction with APCs containing red fluorescent OVA. The use of green fluorescent protein to measure the expression of various proteins has occurred in a variety of in vitro and in vivo models. To identify activated T cells specifically, heterozygous knock-in mice have been generated that have a cDNA for enhanced green fluorescent protein substituted for the IL-2 coding region on one allele [91]. Activated T cells from these IL-2-green fluorescent protein mice up-regulate the expression of the IL-2 gene and consequently synthesize the green fluorescent protein marker. The authors recently demonstrated the presence of these activated cells in vivo in the mouse iris [16]. With both the green fluorescent protein and the brighter yellow fluorescent protein the authors anticipate being able to detect in vivo the expression of various cytokines, such as IL-2, the Th1 cytokine IFN-gamma, or the Th2 cytokine IL-4, in T cells infiltrating the eye. First steps have been undertaken to establish in vivo imaging in human eyes. Toxicity of fluorescent dyes currently used for animal research and movement artifacts of the tissue under investigation amplified by the high magnification necessary for cell research, however, remain the major challenges to study leukocyte migration in human uveitis.
- 1 September 2002
- Published by Dougmar Publishing Group, Inc.
- Vol. 15 (3) , 259-70
Immune mechanisms in uveitis. What can be learned from in vivo imaging?
In many aspects, in vivo imaging is superior to other techniques, such as conventional histology, because it allows the stepwise process of leukocyte migration to be dissected. The potential uses of the in vivo imaging techniques have yet to be achieved. The transfer of lymphocytes with fluorescent dyes can be marked. APCs that ingest fluorescent antigen and use fluorescent antibodies specifically to label different types of APCs in the anterior segment can be identified. Combining these techniques could result in more exciting insights into uveitis and the mechanisms of the immune system. For example, one can confidently expect to be able to observe the extravasation of CFSE-marked DO11.10 T cells and their subsequent interaction with APCs containing red fluorescent OVA. The use of green fluorescent protein to measure the expression of various proteins has occurred in a variety of in vitro and in vivo models. To identify activated T cells specifically, heterozygous knock-in mice have been generated that have a cDNA for enhanced green fluorescent protein substituted for the IL-2 coding region on one allele [91]. Activated T cells from these IL-2-green fluorescent protein mice up-regulate the expression of the IL-2 gene and consequently synthesize the green fluorescent protein marker. The authors recently demonstrated the presence of these activated cells in vivo in the mouse iris [16]. With both the green fluorescent protein and the brighter yellow fluorescent protein the authors anticipate being able to detect in vivo the expression of various cytokines, such as IL-2, the Th1 cytokine IFN-gamma, or the Th2 cytokine IL-4, in T cells infiltrating the eye. First steps have been undertaken to establish in vivo imaging in human eyes. Toxicity of fluorescent dyes currently used for animal research and movement artifacts of the tissue under investigation amplified by the high magnification necessary for cell research, however, remain the major challenges to study leukocyte migration in human uveitis.
- 1 July 2002
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 14 (4) , 337-341
Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies
Anterior uveitis describes inflammation that involves the iris or ciliary body. Anterior uveitis may be part of a systemic illness such as a spondyloarthropathy. It may also arise from an infection such as herpes simplex; be part of an ocular syndrome, such as Fuchs' heterochromic iridocyclitis; be part of trauma, as in cataract surgery; or result from an idiopathic eye disease with a presumed immune pathogenesis. During 2001, progress has been made understanding uveitis in general, as well as specifically, in association with spondyloarthropathy. Here, we review recent insights into anterior uveitis with regard to clinical presentation, immune mechanisms, genetics, and anti-tumor necrosis factor therapy.
- 1 July 2002
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 14 (4) , 337-341
Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies
Anterior uveitis describes inflammation that involves the iris or ciliary body. Anterior uveitis may be part of a systemic illness such as a spondyloarthropathy. It may also arise from an infection such as herpes simplex; be part of an ocular syndrome, such as Fuchs' heterochromic iridocyclitis; be part of trauma, as in cataract surgery; or result from an idiopathic eye disease with a presumed immune pathogenesis. During 2001, progress has been made understanding uveitis in general, as well as specifically, in association with spondyloarthropathy. Here, we review recent insights into anterior uveitis with regard to clinical presentation, immune mechanisms, genetics, and anti-tumor necrosis factor therapy.